OKT3 prophylaxis in liver transplantation.

Area of Science:

• Immunology
• Transplantation Medicine
• Pharmacology

Background:

• Liver transplant recipients often face rejection episodes, necessitating effective immunosuppressive strategies.
• Cyclosporine-based regimens are standard, but alternative prophylactic agents are explored.
• Muromonab-CD3 (OKT3) is a murine monoclonal antibody targeting CD3+ T-cells.

Purpose of the Study:

• To compare the efficacy and safety of OKT3 prophylaxis versus cyclosporine prophylaxis in liver transplant recipients.
• To evaluate early and late rejection rates, infectious complications, and long-term graft and patient survival.

Main Methods:

• A randomized prospective study comparing OKT3, steroids, and azathioprine to cyclosporine, steroids, and azathioprine in liver transplant recipients.
• Patient outcomes including rejection incidence, infectious complications, graft survival, patient survival, liver function, and renal function were monitored.
• Development of anti-OKT3 antibodies and response to OKT3 retreatment were assessed.

Main Results:

• OKT3 prophylaxis resulted in significantly higher early rejection-free rates (72% vs. 41%, P=0.02) within 14 days.
• No significant difference in overall rejection incidence was observed between groups after 14 days through 6.3 months.
• No increased infectious complications were noted with OKT3; however, 39% developed anti-OKT3 antibodies, with some requiring retreatment.

Conclusions:

• OKT3 prophylaxis does not offer long-term benefits over cyclosporine in liver transplant recipients.
• OKT3 should be reserved for treating acute rejection episodes, particularly when cyclosporine is contraindicated.
• The development of anti-OKT3 antibodies and the need for retreatment warrant consideration.